Apnimed Welcomes Kevin R. Lind as New CEO to Propel Growth in Sleep Health Sector

Apnimed Welcomes Kevin R. Lind as New CEO

Apnimed Inc., a late-stage clinical pharmaceutical innovator focusing on therapies for sleep-related breathing disorders, has appointed Kevin R. Lind as its new Chief Executive Officer, effective June 2, 2026. This significant leadership transition comes as the company gears up for its next phase of growth, specifically in the commercialization of its promising drug candidate, AD109.

Lind succeeds founder Lawrence G. Miller, MD, who has effectively led the company since 2018 and will transition to the role of Vice Chair of the Board. With over 25 years of experience in the biopharmaceutical sector, Lind is uniquely qualified to guide Apnimed through this crucial period. His previous role, as President and CEO of Longboard Pharmaceuticals, culminated in a successful acquisition by H. Lundbeck A/S for an impressive $2.6 billion.

In his new position, Lind emphasized the importance of improving outcomes for patients with Obstructive Sleep Apnea (OSA): “I am honored to lead Apnimed at such a critical moment and look forward to working with the team to make a meaningful difference for people living with OSA. In just a few years, the Company has evolved into an exciting late-stage pharmaceutical company.” He stated that the submission of AD109's New Drug Application (NDA) represents a pivotal opportunity for the company, aligning with the substantial unmet need in OSA treatment.

AD109 is designed as a drug to enhance oxygenation during sleep and directly target the neuromuscular issues leading to upper airway collapse in individuals suffering from OSA. This groundbreaking therapeutic is touted as a once-daily oral pill that could revolutionize the traditionally invasive treatment landscape of OSA.

In recognition of the transition, Paul Sekhri has been appointed as the independent Chair of the Apnimed Board of Directors. Sekhri brings over 35 years of experience in the life sciences industry and has a proven track record in both executive leadership and board membership in publicly traded companies, including a significant stint at Longboard Pharmaceuticals.

Dr. Miller expressed confidence in Lind's appointment, noting, “Kevin brings extensive biopharmaceutical leadership and commercial experience, which, combined with his knowledge of Apnimed from his service as Board Chair, gives me the utmost confidence in his ability to lead the Company through its next chapter of growth.”

The Journey Ahead for Apnimed and AD109

As Apnimed embarks on the commercialization journey for AD109, the drug is positioned to fill a critical gap for the 80 million individuals in the United States and over one billion worldwide who suffer from OSA. Recognized as a serious illness, OSA leads to significant health challenges, including cardiovascular problems and reduced life expectancy if left untreated. Therefore, the successful approval and market launch of AD109 could provide an effective, non-invasive treatment option for many patients who currently have limited alternatives.

“While complex treatment options are common in this field, the simplified nature of AD109 could markedly lift the burden on patients, allowing for a better quality of life,” said Lind.

Apnimed’s commitment to innovating in the sleep health sector underlines its mission to make therapy accessible and effective through science-driven solutions. As the company prepares for potential FDA approval of AD109, an impending PDUFA target action date expected in early 2027 marks a critical milestone on their path to fulfill its vision.

As these changes unfold, Lind will navigate the complexities of aligning operational goals with robust market expectations. His success will undoubtedly hinge on strong collaboration with the board, including Miller’s insights as he transitions to his new role.

In conclusion, Apnimed is at a pivotal juncture, with a new leader at the helm poised to enhance both its market position and the lives of countless patients battling sleep-related health issues. With strategic foresight and unwavering commitment to patient health, the outlook for Apnimed and its innovative solutions appears promising.

For more information about Apnimed and their ongoing efforts towards revolutionizing OSA treatment, visit Apnimed’s website. Follow them on X and LinkedIn for updates on their journey and advancements.